Australia
· Delayed Price · Currency is AUD Arovella Therapeutics Statistics
Total Valuation
Arovella Therapeutics has a market cap or net worth of AUD 189.66 million. The enterprise value is 176.94 million.
| Market Cap | 189.66M |
| Enterprise Value | 176.94M |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Arovella Therapeutics has 1.05 billion shares outstanding. The number of shares has increased by 32.32% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.05B |
| Shares Change (YoY) | +32.32% |
| Shares Change (QoQ) | +9.09% |
| Owned by Insiders (%) | 16.07% |
| Owned by Institutions (%) | 11.11% |
| Float | 760.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 86.83 |
| PB Ratio | 16.84 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -20.23 |
| EV / Sales | 90.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -25.12 |
Financial Position
The company has a current ratio of 6.45
| Current Ratio | 6.45 |
| Quick Ratio | 6.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -116.55% and return on invested capital (ROIC) is -73.93%.
| Return on Equity (ROE) | -116.55% |
| Return on Assets (ROA) | -59.16% |
| Return on Capital (ROIC) | -73.93% |
| Revenue Per Employee | 72,301 |
| Profits Per Employee | -323,927 |
| Employee Count | 27 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +111.77% in the last 52 weeks. The beta is -0.04, so Arovella Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | +111.77% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.15 |
| Relative Strength Index (RSI) | 44.51 |
| Average Volume (20 Days) | 1,974,883 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Arovella Therapeutics had revenue of AUD 1.95 million and -8.75 million in losses. Loss per share was -0.01.
| Revenue | 1.95M |
| Gross Profit | 1.95M |
| Operating Income | -8.88M |
| Pretax Income | -8.75M |
| Net Income | -8.75M |
| EBITDA | -8.83M |
| EBIT | -8.88M |
| Loss Per Share | -0.01 |
Balance Sheet
| Cash & Cash Equivalents | 12.71M |
| Total Debt | n/a |
| Net Cash | 12.71M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 11.23M |
| Book Value Per Share | 0.01 |
| Working Capital | 11.11M |
Cash Flow
In the last 12 months, operating cash flow was -6.91 million and capital expenditures -129,341, giving a free cash flow of -7.04 million.
| Operating Cash Flow | -6.91M |
| Capital Expenditures | -129,341 |
| Free Cash Flow | -7.04M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -454.69% |
| Pretax Margin | -448.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -360.80% |
Dividends & Yields
Arovella Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.32% |
| Shareholder Yield | -32.32% |
| Earnings Yield | -5.17% |
| FCF Yield | -3.71% |
Stock Splits
The last stock split was on November 14, 2019. It was a reverse split with a ratio of 0.04.
| Last Split Date | Nov 14, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
Arovella Therapeutics has an Altman Z-Score of 17.6.
| Altman Z-Score | 17.6 |
| Piotroski F-Score | n/a |